Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

Article Abstract:

Transfusion of clones of CD8+ T cells specific for cytomegalovirus (CMV) into people with suppressed immune systems may effectively improve their immunity to the virus. These people often develop CMV disease after bone marrow transplants because of a deficiency of CD8+ T cells that specifically attack the virus. Thirty to 40 days following bone marrow transplant, 14 transplant recipients received four weekly transfusions of CMV-specific CD8+ T cell clones from their donors. All of the recipients gained anti-CMV T cell activity after the transfusions. Furthermore, the 11 recipients who had no anti-CMV T cells before transfusion gained anti-CMV activity equal to that of their donors. No patients developed CMV disease or experienced toxic effects. A lack of CD4+ helper T cells and immunosuppressive drugs may have inhibited the growth and activity of CD8+ T cells in some patients.

Health aspects, Prevention, Cytomegalovirus infections, T cells

---

Does bone marrow transplantation confer a normal life span?

Article Abstract:

Bone marrow transplant recipients may be cured of leukemia or aplastic anemia by the procedure, but they are nevertheless more likely to die in subsequent years than similar, non-transplanted patients. Pre-transplant chemotherapy and radiation, followed by bone marrow transplantation, clearly improves the prognosis of many patients. Those that survive the first two years have an 89% chance of living an additional five years. The life-altering effects of a major, deadly disease and years of treatment makes transplant patients difficult to compare to any other population of patients. In cases where transplantation cures the patient of leukemia, the risk of death from recurrent or other cancer appears to be increased.

United States, Patient outcomes, Mortality, Prognosis, Organ transplant recipients, Leukemia

---

A chance of cure for every patient with chronic myeloid leukemia?

Article Abstract:

Bone marrow transplantation may offer a cure for most patients 50 years old or younger with chronic myeloid leukemia. Favorable outcomes for patients treated with bone marrow from matched, unrelated donors suggest that transplantation is a viable and effective option for many patients, even for those without a suitable donor from within their families. Interferon and other chemotherapeutic agents can induce remission in some patients, but with five-year survival rates as high as 74% after transplantation, the procedure should be offered to most chronic myeloid leukemia patients.

Care and treatment, Chronic myeloid leukemia

Similar abstracts:

• Abstracts: Participation of international medical graduates in graduate medical education and hospital care for the poor
• Abstracts: Acquisition and use of needles and syringes by injecting drug users in Baltimore, Maryland. Deregulation of the sale and possession of syringes for HIV prevention among injection drug users
• Abstracts: Acquisition and use of needles and syringes by injecting drug users in Baltimore, Maryland. part 2 Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws
• Abstracts: Association of weight loss and weight fluctuation with mortality among Japanese American men. Serum total cholesterol and mortality: confounding factors and risk modification in Japanese-American men

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.